Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Genprex ( (GNPX) ) has shared an update.
On May 6, 2025, Genprex announced an exclusive patent license agreement with UTHealth Houston for its lead drug candidate, Reqorsa® Gene Therapy, aimed at treating glioblastoma. This agreement grants Genprex commercial rights and expands its oncology gene therapy portfolio. Previously, in October 2024, Genprex reported positive preclinical data on Reqorsa’s efficacy in glioblastoma, showing promising results in reducing cell viability and migration, which supports further in vivo studies.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on oncology gene therapy technologies. Its primary product is Reqorsa® Gene Therapy, which targets cancer treatment, with a market focus on glioblastoma, a severe brain tumor.
Average Trading Volume: 4,700,298
Technical Sentiment Signal: Sell
Current Market Cap: $7M
For detailed information about GNPX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue